Literature DB >> 23473668

Structural basis of RIP1 inhibition by necrostatins.

Tian Xie1, Wei Peng, Yexing Liu, Chuangye Yan, Jenny Maki, Alexei Degterev, Junying Yuan, Yigong Shi.   

Abstract

Necroptosis is a cellular mechanism that mediates necrotic cell death. The receptor-interacting serine/threonine protein kinase 1 (RIP1) is an essential upstream signaling molecule in tumor-necrosis-factor-α-induced necroptosis. Necrostatins, a series of small-molecule inhibitors, suppress necroptosis by specifically inhibiting RIP1 kinase activity. Both RIP1 structure and the mechanisms by which necrostatins inhibit RIP1 remain unknown. Here, we report the crystal structures of the RIP1 kinase domain individually bound to necrostatin-1 analog, necrostatin-3 analog, and necrostatin-4. Necrostatin, caged in a hydrophobic pocket between the N- and C-lobes of the kinase domain, stabilizes RIP1 in an inactive conformation through interactions with highly conserved amino acids in the activation loop and the surrounding structural elements. Structural comparison of RIP1 with the inhibitor-bound oncogenic kinase B-RAF reveals partially overlapping binding sites for necrostatin and for the anticancer compound PLX4032. Our study provides a structural basis for RIP1 inhibition by necrostatins and offers insights into potential structure-based drug design.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23473668     DOI: 10.1016/j.str.2013.01.016

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  74 in total

Review 1.  Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death.

Authors:  Dimitry Ofengeim; Junying Yuan
Journal:  Nat Rev Mol Cell Biol       Date:  2013-10-16       Impact factor: 94.444

2.  Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors.

Authors:  S M Fayaz; G K Rajanikant
Journal:  J Comput Aided Mol Des       Date:  2014-07-01       Impact factor: 3.686

3.  RIP3 induces apoptosis independent of pronecrotic kinase activity.

Authors:  Pratyusha Mandal; Scott B Berger; Sirika Pillay; Kenta Moriwaki; Chunzi Huang; Hongyan Guo; John D Lich; Joshua Finger; Viera Kasparcova; Bart Votta; Michael Ouellette; Bryan W King; David Wisnoski; Ami S Lakdawala; Michael P DeMartino; Linda N Casillas; Pamela A Haile; Clark A Sehon; Robert W Marquis; Jason Upton; Lisa P Daley-Bauer; Linda Roback; Nancy Ramia; Cole M Dovey; Jan E Carette; Francis Ka-Ming Chan; John Bertin; Peter J Gough; Edward S Mocarski; William J Kaiser
Journal:  Mol Cell       Date:  2014-11-20       Impact factor: 17.970

4.  When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157.

Authors:  Diego Rojas-Rivera; Tinneke Delvaeye; Ria Roelandt; Wim Nerinckx; Koen Augustyns; Peter Vandenabeele; Mathieu J M Bertrand
Journal:  Cell Death Differ       Date:  2017-04-28       Impact factor: 15.828

Review 5.  Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases.

Authors:  Junying Yuan; Palak Amin; Dimitry Ofengeim
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

Review 6.  Ars Moriendi; the art of dying well - new insights into the molecular pathways of necroptotic cell death.

Authors:  James M Murphy; John Silke
Journal:  EMBO Rep       Date:  2014-01-27       Impact factor: 8.807

Review 7.  Small molecule probes for cellular death machines.

Authors:  Ying Li; Lihui Qian; Junying Yuan
Journal:  Curr Opin Chem Biol       Date:  2017-06-16       Impact factor: 8.822

8.  Positive and negative phosphorylation regulates RIP1- and RIP3-induced programmed necrosis.

Authors:  Thomas McQuade; Youngsik Cho; Francis Ka-Ming Chan
Journal:  Biochem J       Date:  2013-12-15       Impact factor: 3.857

9.  TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging.

Authors:  Daichao Xu; Taijie Jin; Hong Zhu; Hongbo Chen; Dimitry Ofengeim; Chengyu Zou; Lauren Mifflin; Lifeng Pan; Palak Amin; Wanjin Li; Bing Shan; Masanori Gomi Naito; Huyan Meng; Ying Li; Heling Pan; Liviu Aron; Xian Adiconis; Joshua Z Levin; Bruce A Yankner; Junying Yuan
Journal:  Cell       Date:  2018-08-23       Impact factor: 41.582

Review 10.  Regulated necrosis: disease relevance and therapeutic opportunities.

Authors:  Marcus Conrad; José Pedro Friedmann Angeli; Peter Vandenabeele; Brent R Stockwell
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.